S&P 500 Healthcare Sector SEC Filings — March 11, 2026

11-03-2026

Milestone Scientific Inc. filed an 8-K on March 11, 2026, under Items 5.03 and 9.01, disclosing amendments to its charter or bylaws along with attached exhibits. The filing, with a size of 4 MB, provides no specific financial metrics or performance data for analysis. No period-over-period comparisons or quantitative changes are detailed.

• ·Company CIK: 0000855683
• ·SIC: 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies)
• ·State of Incorporation: DE
• ·Fiscal Year End: December 31
• ·Business Address: 220 South Orange Avenue, Livingston, NJ 07039

11-03-2026

News Corporation disclosed via 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its $1 billion stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The filing attaches Exhibits 99.1 and 99.2 with the specific ASX disclosures, noting daily transaction reporting requirements if any occur. No specific repurchase volumes or dates are detailed in the main filing body, with forward-looking statements on potential repurchases subject to market conditions.

• ·Date of earliest event reported: March 10, 2026
• ·Filing date: March 11, 2026
• ·Registrant details: Delaware incorporation, Commission File Number 001-35769, IRS EIN 46-2950970
• ·Principal executive offices: 1211 Avenue of the Americas, New York, New York 10036

11-03-2026

Johnson & Johnson (JNJ) filed Definitive Additional Proxy Materials (DEFA14A) on March 11, 2026, as a supplement to its proxy statement under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No specific proposals, financial data, or voting matters are detailed in the provided content.

• ·Filing categorized as Soliciting Material under § 240.14a-12

11-03-2026

Cintas Corporation announced a definitive agreement to acquire UniFirst Corporation for $310 per share in cash and stock, representing a $5.5B enterprise value at 8.0x run-rate trailing 12-month EBITDA, with expected $375M in operating cost synergies within four years and accretion to EPS by the end of the second full year post-closing. The deal enhances service capabilities for 1.5M customers across North America and is expected to close in H2 2026, subject to approvals. Cintas reported preliminary Q3 FY2026 revenue of $2.84B, up 8.9% YoY from $2.61B (organic growth 8.2%), with full results on March 25, 2026.

• ·Transaction multiple of 8.0x run-rate trailing 12 months EBITDA including $375M synergies.
• ·Net leverage ratio at close expected to be 1.5x debt to EBITDA.
• ·Croatti family entities control ~2/3 of UniFirst voting power and entered voting support agreement.
• ·UniFirst Q2 FY2026 results on April 1, 2026; no further conf calls or guidance due to transaction.

11-03-2026

Acacia Research Corporation reported record full-year 2025 revenue of $285.2 million, up 133% YoY from $122.3 million, driven by Manufacturing Operations and Intellectual Property, alongside full-year GAAP Net Income of $21.7 million. Q4 revenue rose 3% YoY to $50.1 million with Total Company Adjusted EBITDA of $17.4 million, up from $4.9 million; however, Energy Operations revenue declined 8% YoY in Q4 to $16.0 million, Industrial Operations revenue fell 11% YoY to $7.3 million and full-year Industrial revenue dropped 7% YoY to $28.3 million, while Industrial Q4 Adjusted EBITDA decreased 34% YoY.

• ·Operated Segment Adjusted EBITDA full-year 2025: $96.4M, up from $35.7M in 2024.
• ·Manufacturing Operations full-year revenue: $114.8M vs $23.2M in 2024.
• ·Intellectual Property Operations full-year revenue: $78.4M, up ~301% YoY.
• ·Q4 Manufacturing Operations Adjusted EBITDA: $1.1M vs $2.4M prior year (decline).
• ·Full-year Free Cash Flow: $64.7M.

11-03-2026

Minerva Neurosciences reported FY 2025 financial results with $80M gross proceeds from an October 2025 private placement, boosting cash to $82.4M from $21.5M at year-end 2024, and plans to initiate a confirmatory Phase 3 trial for roluperidone in Q2 2026 with topline data in 2H 2027. However, GAAP net loss widened dramatically to $293.4M for FY 2025 from $1.4M net income in 2024, driven by $321.5M non-cash loss on convertible preferred stock and warrant issuance, while R&D expenses declined 51% YoY to $5.8M but G&A rose 12% in Q4 to $2.8M. Non-GAAP adjusted net loss improved to $16.0M from $19.3M for the full year.

• ·Warrant liability fair value at Dec 31, 2025: $171.5M, with $45.4M non-cash gain on change in fair value for FY 2025.
• ·Non-GAAP total liabilities: $2.3M at Dec 31, 2025 vs $2.8M at Dec 31, 2024 (slight decline).
• ·Q4 GAAP net loss per share: $25.51 vs $0.56 prior year; FY GAAP net loss per share: $34.67 vs $0.19 net income per share prior year.

11-03-2026

Bread Financial Holdings, Inc. filed an 8-K on March 11, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing a press release with a performance update as of and for the period ended February 28, 2026 (Exhibit 99.1). The press release is furnished but not deemed 'filed' under Section 18 of the Exchange Act. No specific financial metrics or period-over-period comparisons were detailed in the filing body.

• ·Securities registered: Common Stock (BFH, NYSE); Depository Shares for 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (BFH PrA, NYSE).

11-03-2026

Sagimet Biosciences Inc. reported a net loss of $51.0M for the year ended December 31, 2025, up 12% YoY from $45.6M in 2024, driven by a 4% increase in total operating expenses to $56.9M despite flat R&D expenses at 2% growth. While clinical development costs declined 12% YoY, manufacturing expenses rose 34% and G&A increased 11%, with cash used in operations worsening to $45.7M from $42.4M, leading to a net cash decrease of $40.8M. Other income fell 34% to $5.9M, and the company highlighted ongoing risks including cash sufficiency and lack of marketing capabilities.

• ·External R&D subtotal remained nearly flat at -1% YoY ($34.3M vs $34.6M).
• ·Investing activities provided $4.6M cash inflow in 2025 vs $61.7M outflow in 2024.
• ·Financing activities generated only $0.3M in 2025 vs $104.8M in 2024.

11-03-2026

Kewaunee Scientific reported Q3 FY26 sales of $69.4M, up 3.3% YoY from $67.2M, driven by strong 21.4% growth in the International segment to $18.4M, though Domestic sales declined 2.0% to $51.0M. Pre-tax earnings rose 25.8% to $1.6M and EBITDA was relatively flat at $3.8M, but net earnings fell to $0.7M from $1.4M with diluted EPS at $0.23 versus $0.45 YoY, amid lower manufacturing volumes and a reduced order backlog of $183.2M (down 17.3% YoY from $221.6M).

• ·YTD nine months FY26 net sales $210.6M (adjusted), up from adjusted $163.3M prior year.
• ·Corporate segment pre-tax net loss $3.1M, relatively flat YoY.
• ·Long-term debt net of sale-leaseback $16.3M, down from $34.1M at April 30, 2025.
• ·Nu Aire acquisition closed November 1, 2024.

11-03-2026

CNB Financial Corp's total assets grew 35.6% YoY to $8.4B, driven by net loans expanding 40.9% to $6.4B and deposits increasing 30.8% to $7.0B, with shareholders' equity up 42.8% to $872.1M. Net income rose to $66.1M from $54.6M, supported by net interest income of $242M (up from $187.5M) and a net interest margin improving to 3.65%. However, regulatory capital ratios declined (total risk-based to 14.78% from 16.16%; Tier 1 to 12.65% from 13.41%), and tangible book value per share fell to $23.48 from $24.24.

• ·Nonaccrual loans decreased to $39.8k (0.61% of loans) from $56.3k (1.22%) YoY.
• ·Allowance for credit losses steady at 1.03% of total loans.
• ·Merger-related expenses (net of tax) $11.6M; adjusted net income to common $73.4M.
• ·PPNR (non-GAAP) $91.3M vs $76.6M; adjusted PPNR $105.1M after $13.8M merger costs.

11-03-2026

Triumph Financial, Inc. filed a DEFA14A notice on March 11, 2026, regarding the availability of proxy materials for its Annual Meeting of Shareholders on April 23, 2026, for shareholders of record as of February 24, 2026. Key proposals include the election of nine directors, advisory approval of executive compensation, and ratification of the independent registered public accounting firm, with the Board recommending a FOR vote on Proposals 1, 2, and 3. No financial metrics or performance data are disclosed in this notice.

• ·Paper materials ordering: Internet www.investorelections.com/TFIN, Call 1-866-648-8133, Email paper@investorelections.com (include 12-digit control number).
• ·Proposal 4: To transact any other business properly coming before the meeting or adjournments.

11-03-2026

PNC Financial Services Group reported strong 2025 financial performance with net income increasing 18% YoY to $7.0B, revenue up 7% to $23.1B, diluted EPS rising 21% to $16.59, loans growing 5% to $331.5B, and deposits up 3% to $440.9B. Non-interest expenses rose 2% YoY to $13.8B, but the company achieved 5% positive operating leverage and returned $3.9B to shareholders via dividends ($2.6B) and repurchases ($1.2B). Post-year end, PNC closed its acquisition of FirstBank on January 5, 2026, adding $26B in assets, $16B in loans, and $23B in deposits, significantly expanding its presence in Colorado and Arizona.

• ·4th largest branch network in the U.S. with presence in the 30 largest U.S. markets.
• ·CET1 capital ratio improved to 10.6% from 10.5%.
• ·Book value per common share $140.44 (2025) vs $122.94 (2024).
• ·Tangible book value per common share $112.51 (2025) vs $95.33 (2024).
• ·Post-acquisition: 120 branches in Colorado; >70 in Arizona; leading bank in Denver by retail deposit share (20%) and branch share (14%).
• ·2025 Form 10-K filed February 20, 2026; proxy materials accessible from March 11, 2026.

11-03-2026

HBT Financial, Inc. filed an 8-K on March 11, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. No specific details on the agreement, obligation size, strategic rationale, or financial impacts are disclosed in the provided filing summary. This is a multi-item filing with no quantitative metrics, period-over-period comparisons, or forward-looking guidance mentioned.

11-03-2026

11-03-2026

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed Amendment No. 3 to its S-1 registration statement on March 11, 2026, for the resale of up to 4,689,177 shares of common stock by Registered Stockholders via a direct listing on Nasdaq Capital Market, with no proceeds to the company. The company engaged RBW Capital Partners LLC as financial advisor (to receive 271,762 shares as 1.75% compensation) and placement agent for a $7.5M private placement of 937,500 shares of Series C Preferred Stock at $10.00 per share through Dawson James Securities. Listing is contingent on Nasdaq approval, with potential volatility noted due to the novel direct listing structure.

• ·RBW engagement agreement executed February 10, 2025.
• ·Series C conversion price: lower of $10.00 or 80% of 5-day avg closing price, floor $1.00.
• ·Resale registration for Series C underlying common stock and advisory shares to be filed within 10 days of Nasdaq listing.
• ·Company is emerging growth company and smaller reporting company.
• ·Nevada incorporation, SIC 2834 (Pharmaceutical Preparations), EIN 20-5274304, CIK 0002079272.

11-03-2026

Evofem Biosciences, Inc.'s 10-K filing raises substantial doubt about its ability to continue as a going concern, citing material weaknesses in internal controls as of December 31, 2025 and 2024, over 90 days past due on significant vendor obligations, notices of default from Future Pak, LLC, and ongoing significant losses with negative cash flows. The company faces challenges in raising additional capital, remediating controls, commercializing PHEXX and SOLOSEC, and complying with debt arrangements, with no indications of near-term profitability. Risks include potential asset seizures, regulatory enforcement, and failure to meet Nasdaq or other listing standards.

• ·Over 90 days past due on significant vendor obligations.
• ·Material weaknesses in internal controls identified as of December 31, 2025 and December 31, 2024.
• ·FDA approval for PHEXX (as Femidence in Nigeria) for pregnancy prevention and SOLOSEC for BV and trichomoniasis treatment.

11-03-2026

Costco Wholesale Corp reported strong Q2 results for the 12 weeks ended February 15, 2026, with total revenue increasing 9.3% YoY to $69.6B, driven by 9.1% net sales growth to $68.2B and 13.6% rise in membership fees to $1.4B; net income grew 13.8% to $2.0B. For the 24 weeks YTD, total revenue rose 8.8% YoY to $136.9B, with net income up 12.5% to $4.0B, while operating cash flow surged 28% to $7.7B. Balance sheet remains solid with cash and equivalents at $17.4B, up from $14.2B at FY end, and total assets expanding to $83.6B.

• ·Diluted EPS for 12 weeks: $4.58 (up from $4.02 YoY)
• ·Diluted EPS for 24 weeks: $9.08 (up from $8.06 YoY)
• ·Operating income 12 weeks: $2.6B (up 12.5% YoY)
• ·Merchandise inventories: $19.0B as of Feb 15, 2026 (up from $18.1B at FY end)
• ·Long-term debt excluding current: $5.7B (stable YoY)
• ·Stock-based compensation expense: $655M for 24 weeks (up from $616M YoY)

11-03-2026

On March 11, 2026, Rodger Levenson, Chairman, President and CEO of WSFS Financial Corporation, adopted a Rule 10b5-1 pre-arranged stock trading plan for the potential exercise of vested stock options and sale of up to 65,446 shares of common stock between June 10, 2026, and June 30, 2027, for personal financial and estate planning purposes. As of the filing date, Mr. Levenson beneficially owns approximately 247,000 shares and will retain ownership well above the company's 100,000 share stock ownership guidelines even if all planned sales occur.

11-03-2026

CID Holdco reported explosive revenue growth of 3,261.7% YoY to $5.8M in 2025 from $0.17M in 2024, with gross profit surging 1,970.3% to $2.7M. However, gross margin declined sharply by 38.4% to 46.0% from 74.7%, sales and marketing expenses increased 34.9% to $3.7M, and net cash used in operating activities more than quadrupled to -$13.3M from -$3.3M. Auditors expressed substantial doubt about the company's ability to continue as a going concern due to liquidity concerns.

• ·Technology features low-cost passive transponders (less than a tenth the cost of competitors' active transponders).
• ·Net cash used in investing activities increased to -$1.8M in 2025 from -$0.8M in 2024.

11-03-2026

Biogen Inc. announced on March 11, 2026, that Susan H. Alexander, its Chief Legal Officer, will depart effective at the end of May 2026. The company has initiated a search for a successor to fill the Chief Legal Officer position. No details were provided on the reasons for departure or any compensatory arrangements.

• ·Biogen Inc. (CIK: 0000875045, EIN: 33-0112644) is incorporated in Delaware with principal offices at 225 Binney Street, Cambridge, MA 02142.
• ·Common Stock ($0.0005 par value) trades as BIIB on Nasdaq Global Select Market.

11-03-2026

On March 11, 2026, Stryker Corporation disclosed a cybersecurity incident impacting its Microsoft environment, causing global disruptions to certain IT systems and business applications with an uncertain restoration timeline. The company activated its response plan with external support, detected no ransomware or malware, believes the incident is contained, and has implemented business continuity measures to support customers. However, the full scope, nature, and potential operational and financial impacts remain unknown, and no material impact has been determined yet.

• ·Incident investigation ongoing with internal and external cybersecurity experts.
• ·Registrant details: Michigan incorporation, CIK 0000310764, IRS 38-1239739, headquarters at 1941 Stryker Way, Portage, Michigan 49002.

11-03-2026

On March 6, 2026, the Compensation Committee of Lifeway Foods, Inc. approved the forms of Notice of Deferred Time-Vested Cash Award and Notice of Deferred Performance-Based Cash Award under the company's 2022 Omnibus Incentive Plan. These forms outline vesting schedules, forfeiture conditions, payment terms (cash or potentially shares with Danone's consent), and compliance with Section 409A, applicable to certain officers and participants. No specific award amounts or recipients were disclosed in the filing.

• ·Awards vest based on continued employment, with accelerated vesting upon death or disability (Qualifying Termination Event).
• ·In a Change of Control, Plan Article 17 applies.
• ·Payment due as soon as practicable after vesting, no later than March 15th of the following calendar year.

11-03-2026

Total operating revenues edged up 0.4% YoY to $176.4M for the year ended December 31, 2025, with flat overall growth despite a 1.0% increase in RNG production volumes to 5,644 MMBtu; however, RNG revenues declined 1.4% to $155.7M and electricity revenues fell 2.9% to $17.2M. Net income dropped sharply 82.0% to $1.7M, operating income plunged 94.7% to $0.9M, and Adjusted EBITDA decreased to $35.6M from $42.6M, driven by higher operating expenses (+10.0%), O&M expenses (+16.5%), and depreciation (+27.5%). Cash from operating activities fell to $30.3M from $43.8M amid heavy investing outflows of $120.5M.

• ·Cash and cash equivalents decreased to $24.2M from $46.0M.
• ·Property, plant and equipment, net increased to $341.4M from $252.3M.
• ·Long-term debt rose significantly to $126.0M from $43.8M.
• ·Total stockholders' equity grew to $263.1M from $257.4M.
• ·Impairment loss increased 103.7% to $3.2M.

11-03-2026

abrdn National Municipal Income Fund (NYSE: VFL) adjourned its Special Shareholder Meeting held on March 11, 2026, to April 1, 2026, at 11:00 am Eastern Time, to solicit additional proxies and achieve quorum. The meeting concerns approval of an Agreement and Plan of Reorganization with MFS Municipal Income Trust (NYSE: MFM), which the Board of Trustees unanimously recommends. Aberdeen Investments reported approximately $525B in assets under management as of December 31, 2025.

• ·Joint Proxy Statement/Prospectus available on www.sec.gov
• ·Fund fiscal year end: March 30

11-03-2026

Anixa Biosciences, Inc. held its 2026 annual stockholder meeting on March 10, 2026, re-electing directors Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr., approving executive compensation on a non-binding advisory basis, and ratifying Haskell & White LLP as auditors for the fiscal year ending October 31, 2026. While all proposals passed, significant opposition was evident with 1.7M-2.0M shares withheld from certain directors and 2.97M votes against executive compensation out of 9.1M cast. Voter turnout was 20.8M shares present out of 33.4M eligible.

• ·Withheld votes: Dr. Amit Kumar (218,238 shares), Dr. Arnold Baskies (1,710,151 shares), Emily Gottschalk (1,886,761 shares), Lewis H. Titterton, Jr. (1,959,312 shares)
• ·Executive compensation abstentions: 137,032 votes
• ·Auditor ratification: 191,432 votes against, 187,368 abstaining
• ·Presentation materials attached as Exhibit 99.1 for potential future investor use

11-03-2026

CI&T Inc (CINT) filed its 20-F Annual Report on March 11, 2026, outlining extensive business risks including global economic volatility, client concentration and retention challenges, intense competition, talent attrition, pricing pressures, and geopolitical instability from conflicts in Ukraine, Russia, and the Middle East. The disclosure emphasizes uncertainties in sustaining revenue growth, acquisition integration difficulties, cybersecurity threats, and regulatory changes in Brazil, with no quantitative financial data provided in the excerpt. While highlighting innovation needs in AI and technology transformation, it warns of potential revenue declines from client losses or economic downturns.

• ·Risks tied to Brazilian economic factors including GDP growth, inflation, interest rates, and political instability.
• ·Exposure to foreign currency fluctuations and U.S. trade policy changes.
• ·Dependence on limited industry verticals for revenue.

11-03-2026

On March 10, 2026, Lifeward Ltd. received notice from Nasdaq's Listing Qualifications Hearings Department that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement, by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive business days from February 24 to March 9, 2026. This matter is now closed with no further action required.

• ·Filing date: March 11, 2026

11-03-2026

MSCI Inc. filed Definitive Additional Proxy Materials (DEFA14A) with the SEC on March 11, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is marked as filed by the registrant with no fee required. No specific proposals, financial data, or changes are detailed in the provided filing header.

11-03-2026

C&F Financial Corporation's 2026 proxy statement outlines the April 21, 2026 annual meeting agenda, including election of five Class III directors, advisory approval of executive compensation, and ratification of Yount, Hyde & Barbour, P.C. as auditors. For 2025, the company reported net income of $27.0M (up 36% YoY from $19.9M in 2024) and EPS of $8.29 (up 38% YoY), with ROE at 11.11% (up 23% YoY but down from 11.68% in 2023) and ROA at 1.01% (up 26% YoY). Book value per share rose 15% YoY to $80.64, while CEO incentive compensation constituted 52% of total direct pay, aligned with improved peer rankings (65th percentile composite ROA/ROE, 78th percentile 3-year ROTCE).

• ·Record date for shareholders: February 13, 2026.
• ·Annual meeting location: 3600 LaGrange Parkway, Toano, Virginia.
• ·Board composition: 2 management members, 11 independent directors.
• ·Peer group for performance measures: 46-47 other banks.

11-03-2026

Peapack Gladstone Financial Corp (PGC) reported net income of $37.3M for 2025, up 13.1% YoY from $33.0M, driven by robust net interest income growth of 34.8% to $200.9M and loan expansion of 13.4% to $6.25B, with total assets reaching $7.53B and assets under management at $13.1B. However, operating expenses rose 17.9% to $207.2M, provision for credit losses surged to $23.5M from $7.5M, and regulatory total capital ratio declined to 12.68% from 14.84%, while net income remained below 2023's $48.9M. Asset quality improved with nonperforming loans dropping to 1.09% from 1.82% of total loans.

• ·Basic EPS $2.12 in 2025, up from $1.87 in 2024.
• ·ROA 0.52% in 2025, slightly up from 0.50% but down from 0.76% in 2023.
• ·ROE 5.95% in 2025, up from 5.61% but down significantly from 8.77% in 2023.
• ·Net charge-offs to average loans 0.44% in 2025, up sharply from 0.01% in 2024.
• ·Noninterest-bearing deposits to total deposits improved to 21.68% from 18.16%.
• ·Cash dividends declared per share flat at $0.20 across periods.

11-03-2026

Hewlett Packard Enterprise Company (HPE) filed a DEFA14A Definitive Additional Proxy Materials on March 11, 2026, indicated by the filename 'a2026defa-14ashareincrease.htm' suggesting matters related to share increase. No substantive details, financial metrics, or period-over-period comparisons are provided in the filing header. This appears to be supplemental proxy information ahead of a shareholder meeting.

11-03-2026

SELLAS Life Sciences Group, Inc. (SLS), a pharmaceutical preparations company (SIC 2834), filed an 8-K on March 11, 2026, under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits), with accession number 0001104659-26-026384 and file size of 193 KB. The filing lists recent activity including multiple Schedule 13G/A amendments for beneficial ownership and prior financial reports, but no specific financial metrics or period-over-period comparisons are detailed in the provided index. No improvements or declines are quantifiable from the metadata.

• ·CIK: 0001390478
• ·Business Address: 7 Times Square Suite 2503, New York, NY 10036
• ·Phone: 646-200-5278
• ·Fiscal Year End: December 31
• ·State of Incorporation: DE
• ·Recent filings include Schedule 13G/A on 2026-02-17 and 2026-01-30 indicating changes in major shareholder beneficial ownership

11-03-2026

Tilly's Q4 FY2025 net sales rose 5.3% YoY to $155.1M with comparable sales up 10.1%, driving the first profitable Q4 since FY2021 with net income of $2.9M ($0.10/share) versus a $13.7M loss prior year. However, full-year FY2025 net sales declined 2.8% to $553.6M despite flat comparable sales growth of +0.3%, resulting in an improved but still significant net loss of $17.5M ($0.58/share) from $46.2M prior year. Store count fell 7.1% to 223, inventories dropped 10.8%, and Q1 FY2026 outlook projects 16-22% comp sales growth but a net loss of $8.0M-$10.1M.

• ·Q4 FY2025 gross profit $51.5M (33.2% of sales) vs $38.3M (26.0%) prior year.
• ·FY2025 capex $4.7M vs $8.2M prior year.
• ·Q1 FY2026 net sales outlook $119M-$125M.
• ·Promotion of Michael J. Cingolani to Chief Merchandising Officer on March 10, 2026.
• ·Total assets $310.8M as of Jan 31, 2026 vs $342.5M prior year.